News on countries and Eli Lilly

Eli Lilly releases Zepbound obesity drug in Japan, targeting 'hidden' fat

Read on: Nikkei

Eli Lilly releases obesity drug in Japan, targeting 'hidden' fat

Read on: Nikkei

Healthy Returns: Novo Nordisk scoops up Chinese obesity drug to compete with Eli Lilly

Read on: CNBC News

Eli Lilly's Alzheimer's drug is rejected by EU regulators over brain swelling risk, despite U.S. approval

Read on: Quartz

Eli Lilly wants to make drugs in America. First it wants a tax cut

Read on: Quartz

Eli Lilly unveils $27bn US investment as corporate America seeks to woo Trump

Read on: Financial Times

Eli Lilly to launch diabetes, obesity drug in India next year

Read on: Times of India

Eli Lilly to trial use of weight loss drugs to combat unemployment in UK

Read on: CNBC News

Eli Lilly obesity drug on track for Japan approval next year: CEO

Read on: Nikkei

Eli Lilly wins US approval for early-stage Alzheimer's treatment

Read on: Financial Times

Eli Lilly chases $100bn weight loss market with $5.3bn US investment

Read on: Financial Times

US regulator delays decision on Eli Lilly's Alzheimer's drug

Read on: Financial Times

Eli Lilly could launch obesity drug in India next year

Read on: Reuters

Norway's giant wealth fund touts possibility of Novo Nordisk, Eli Lilly joining the trillion-dollar club

Read on: CNBC News